Development and Commercialization of Biosimilars in India - The author aims to present the current status of India in this context, the challenges that need to be overcome, and some recommendations th

ADVERTISEMENT

Development and Commercialization of Biosimilars in India
The author aims to present the current status of India in this context, the challenges that need to be overcome, and some recommendations that may alleviate these challenges.


BioPharm International
Volume 24, Issue 11, pp. 36-40

REFERENCES

1. G. Walsh, Nature Biotechnol. 28 (9) 917–924 (2010).

2. J. Hodgson, Nature Biotechnol. 27 (11) 963–965 (2009).

3. P. Narang, Datamonior Biosimilar Series 2008 (Datamonitor, London. June 2009).

4. C. Chakraborty and G. Agoramoorthy, Biotechnology Advances 28 (1) 1–6 (2010).

5. S. Chaturvedi, The Indian Jrnl. of Labour Econ. 52 (2) 693–712 (2009).

6. S. Natesh and M. Bhan, Current Sci. 97, 157–169 (2009).

7. C.J. Mathew, Business Standard (Oct. 2007), p. 16.

8. K. Jayaraman, Nature Biotechnol. 28 (9) 883–884 (2010).

9. E.S. Langer, Gen. Engin. & Biotechnol. News 30 (5) 2010

10. A.S. Rathore, Trends in Biotechnol, 27, (12) 698–705 (2009).

11. A.S. Rathore and I.S. Krull, LCGC North America 28, 598–600 (2010).

12. J.F. Tremblay, Chemical & Engin. News (Aug. 2010), p. 23.

13. A. S. Rathore and H. Winkle H, Nature Biotechnol. 27 (1) (2009) 26–34 (2009).

14. A.S. Rathore, Trends in Biotechnology, 27 (9), 546–553 (2009).


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Approves Pfizer's Trumenba for the Prevention of Meningitis B
October 30, 2014
EMA: Extrapolation Across Indications for Biosimilars a Possibility
October 30, 2014
Bristol-Myers Squibb Announces Agreement to Acquire HER2-Targeted Cancer Treatment
October 29, 2014
Contract Research and Manufacturing Organization Paragon Bioservices Raises $13 Million
October 28, 2014
Yale and Gilead Extend Sequencing Initiative
October 28, 2014
Author Guidelines
Source: BioPharm International,
Click here